— Partnership with Parkinson Research Group Advisory Panel to collaborate on Parkinson’s Illness Program —
— Presentation at AD/PD™ 2021 Underscores Relevance of Cortexyme’s Method —
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical firm targeted on Alzheimer’s and different degenerative illnesses, introduced that it has partnered with the Parkinson Research Group (PSG) to type an Advisory Board to leverage the group’s experience and additional develop the corporate’s Parkinson’s illness (PD) program. As well as, Cortexyme will current new information additional demonstrating the position of Porphyromonas gingivalis (P. gingivalis) within the growth of Alzheimer’s illness at AD/PD™ 2021, the 15th Worldwide Convention on Alzheimer’s & Parkinson’s Illnesses, which is being held nearly March 9-14, 2021.
Hubert Fernandez, M.D., Co-Chair of the Parkinson Research Group Government Committee and Chair of the PSG Credentialing Committee, and a member of the newly created Advisory Board, said: “I look ahead to working with my colleagues on the Advisory Board. We’re collectively desirous to additional perceive the mechanism of gingipain inhibition and its potential to enhance the lives of sufferers affected by Parkinson’s illness. There’s a super unmet medical want for PD, and the potential hyperlink between P. gingivalis and PD calls for additional exploration.”
Together with Fernandez, the brand new Cortexyme/PSG Advisory Board is comprised of professional researchers throughout the PD discipline:
Patrik Brundin, M.D., Ph.D., Honorary Visitor to the PSG
Eric Macklin, Ph.D., PSG Government Committee Member
Zoltan Mari, M.D., Co-Chair of the PSG Motor Options of PD Working Group
Andrew Siderowf, M.D., PSG Government Committee Member
“Our partnership with the PSG demonstrates the significance of Cortexyme’s proof to this point and the potential to learn sufferers affected by Parkinson’s illness,” stated Michael Detke, M.D., Ph.D., Cortexyme’s Chief Medical Officer. “We’re happy to companion with the PSG and look ahead to advancing our work in Parkinson’s illness as we make progress in direction of bettering affected person outcomes.”
Mounting proof helps the position of P. gingivalis in Parkinson’s illness, together with analysis supporting the epidemiological hyperlink between periodontal illness and Parkinson’s illness and rodent research demonstrating that oral P. gingivalis an infection causes alpha-synuclein manufacturing and degeneration of dopamine-producing neurons within the substantia nigra of the mind. For additional particulars, go to www.cortexyme.com/science.
AD/PD 2021 Presentation Furthers Hyperlink Between P. gingivalis and Neurodegeneration
Cortexyme may even current analysis (poster 131/summary 1544) at AD/PD 2021 additional reinforcing Cortexyme’s foundational analysis on P. gingivalis’ position in AD and new strategies to detect the presence of P. gingivalis within the human mind.
Within the poster, scientists on the College of Auckland and Cortexyme report new strategies to find out the ultrastructural localization of the arginine-gingipain (Rgp) virulence issue secreted by P. gingivalis within the human AD mind utilizing electron microscopy. The researchers will report on the intracellular organelles in AD mind cells that Rgp co-localizes with, offering perception for the primary time on why some sub-cellular organelles in AD neurons and astrocytes are broken.
“This analysis provides to the rising physique of proof that reveals the presence of gingipains within the human AD mind and the validation of recent electron microscopy strategies that may be leveraged for future analysis into sub-cellular localization of gingipains inside neurons and astrocytes,” stated Stephen Dominy, M.D., Cortexyme’s Co-Founder and Chief Scientific Officer.
View the summary “Ultrastructural localization of Porphyromonas gingivalis RgpB virulence issue within the center temporal gyrus (MTG) of the Alzheimer’s illness human mind” here on Cortexyme’s web site following the convention.
Cortexyme, Inc. (Nasdaq: CRTX) is a medical stage biopharmaceutical firm pioneering upstream therapeutic approaches designed to enhance the lives of sufferers recognized with Alzheimer’s and different degenerative illnesses. Based mostly upon the proof generated to this point, Cortexyme is at the moment advancing its lead therapeutic candidate, atuzaginstat (COR388), within the GAIN Trial, an ongoing Section 2/3 medical trial in sufferers with gentle to reasonable Alzheimer’s illness. Cortexyme is concentrating on a selected, infectious pathogen discovered within the mind and different organs and tied to degeneration and irritation in people and animal fashions. To study extra about Cortexyme, go to www.cortexyme.com or comply with @Cortexyme on Twitter.
Statements on this press launch comprise “forward-looking statements” which can be topic to substantial dangers and uncertainties. Ahead-looking statements contained on this press launch could also be recognized by means of phrases resembling “anticipate,” “anticipate,” “imagine,” “will,” “could,” “ought to,” “estimate,” “mission,” “outlook,” “forecast” or different related phrases. Examples of forward-looking statements embrace, amongst others, statements we make relating to the partial medical maintain and ongoing correspondence with the FDA, and its associated affect on the timing and success of our medical trials, together with with respect to atuzaginstat, the double-blind, placebo-controlled randomized part of the GAIN Trial and open-label extension part; the timing of bulletins and updates referring to our medical trials and associated information; the potential therapeutic advantages, security and efficacy of our product candidate or library of compounds; statements about our capacity to acquire, and the timing referring to, and regulatory submissions and approvals with respect to our drug product candidate. Ahead-looking statements are primarily based on Cortexyme’s present expectations and are topic to inherent uncertainties, dangers and assumptions which can be troublesome to foretell and will trigger precise outcomes to vary materially from what we anticipate. Additional, sure forward-looking statements are primarily based on assumptions as to future occasions that will not show to be correct. Components that might trigger precise outcomes to vary embrace, however will not be restricted to, the dangers and uncertainties described within the part titled “Danger Components” in our Annual Report on Type 10-Ok filed with the Securities and Change Fee (SEC) on March 1, 2021, our Quarterly Report on Type 10-Q filed with the SEC on November 12, 2020, and different studies as filed with the SEC. Ahead-looking statements contained on this press launch are made as of this date, and Cortexyme undertakes no obligation to replace such info besides as required underneath relevant regulation.
View supply model on businesswire.com: https://www.businesswire.com/news/home/20210308005240/en/
Chief Working Officer
Corey Davis, Ph.D.
For Cortexyme, Inc.